查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1304399

α发射体(α发射体)市场:各放射性核种类型，各医疗用途，各地区 - 市场规模，占有率，展望，机会分析，2023年～2030年

Alpha Emitter Market, By Type of Radionuclide (Radium, Actinium, and Lead ), By Medical Applications, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 171 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场动态:

癌症负担的增加、老年人口的增加、癌症治疗中靶向α疗法（TAT）的使用增加、对TAT潜在益处的认识的提高以及研究和开发的增加预计将推动全球癌症治疗的增长阿尔法发射器市场。

本调查的主要特征

  • 本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球α发射体(α发射体)市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
  • 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
  • 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
  • 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球α发射体(α发射体)市场的主要参与者之企业简介。
  • 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 全球α发射体(α发射体)市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以透过全球α发射体(α发射体)市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

目录

第1章 调查目的与前提条件

  • 调查目的
  • 前提条件
  • 简称

第2章 市场概况

  • 报告概要
    • 市场定义和范围
  • 摘要整理
  • 连贯·机遇·地图(COM)

第3章 市场动态，法规，趋势分析

  • 市场动态
    • 癌症负担增加和老年人口增加
    • 严格的法规和高资本投入的需求
    • 靶向 α 疗法 (TAT) 的采用/使用增加
  • 影响分析
  • 主要的焦点
  • 法规情势
  • 产品上市/核准
  • PEST分析
  • 波特分析
  • 合併和收购方案

第4章 α发射体的全球市场-冠状病毒(COVID-19)流行的影响

  • COVID-19流行病学
  • 供给面和需求面的分析
  • 经济影响

第5章 α发射体的全球市场:各放射性核种类型，2023-2030年

  • 镭(Ra-223)
  • 锕(Ac-225)
  • 铅(Pb-212)

第6章 α发射体的全球市场:各医疗用途，2023-2030年

  • 前列腺癌症
  • 骨转移
  • 卵巢癌症
  • 胰臟癌症
  • 内分泌肿瘤
  • 其他的医疗用途

第7章 α发射体的全球市场:各地区，2023-2030年

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东·非洲

第8章 竞争情形

  • Bayer AG
  • Alpha Tau Medical Ltd.
  • Fusion Pharmaceuticals
  • Telix Pharmaceuticals Ltd.
  • Orano Group(Orano Med)
  • NOVARTIS AG(Endocyte Inc.)
  • Actinium Pharmaceutical Inc.

第9章 章节

  • 调查手法
  • 关于出版社
简介目录
Product Code: CMI5534

Alpha emitters play a significant role in the treatment of different types of cancer. Targeted alpha therapy (TAT) is a therapeutic option in patients with multiple micro-metastases. Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancer. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine.

Market Dynamics:

Increase in burden of cancer, rise in geriatric population, increase in use of targeted alpha therapy (TAT) for cancer treatment, rise in awareness about the potential benefits of TAT, and increase in research and development are expected to propel the growth of the global alpha emitter market.

For instance, in July 2021, Alpha Tau Medical Ltd. and Healthcare Capital Corporation signed an agreement to further expand Alpha Tau's clinical strategy, including the pursuit of FDA (Food and Drug Administration) marketing authorization, a broad array of R&D (research and development) activities, expanding manufacturing capacity, and preparing for commercialization.

Key features of the study:

  • This report provides in-depth analysis of the global alpha emitter market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global alpha emitter market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Bayer AG, Alpha Tau Medical Ltd., Fusion Pharmaceuticals, Telix Pharmaceuticals, Orano Group (Orano Med), NOVARTIS AG (Endocyte Inc.), and Actinium Pharmaceutical Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global alpha emitter market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global alpha emitter market.

Detailed Segmentation:

  • Global Alpha Emitter Market, By Type of Radionuclide:
    • Radium (Ra-223)
    • Actinium (Ac-225)
    • Lead (Pb-212)
  • Global Alpha Emitter Market, By Medical Applications:
    • Prostate Cancer
    • Bone Metastases
    • Ovarian Cancer
    • Pancreatic Cancer
    • Endocrine Tumors
    • Other Medical Applications
  • Global Alpha Emitter Market, By Geography:
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • Latin America
  • Company Profiles:
    • Bayer AG
    • Alpha Tau Medical Ltd.
    • Fusion Pharmaceuticals
    • Telix Pharmaceuticals Ltd.
    • Orano Group (Orano Med)
    • NOVARTIS AG (Endocyte Inc.)
    • Actinium Pharmaceutical Inc.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type of Radionuclide
    • Market Snapshot, By Medical Applications
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in burden of cancer and rise in geriatric population
    • Stringent regulations and need for high capital investment
    • Increase in adoption/use of targeted alpha therapy (TAT)
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Alpha Emitter Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Alpha Emitter Market, By Type of Radionuclide, 2023-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Radium (Ra-223)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Actinium (Ac-225)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Lead (Pb-212)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Alpha Emitter Market, By Medical Applications, 2023-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Bone Metastases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Pancreatic Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Endocrine Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other Medical Applications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Alpha Emitter Market, By Geography, 2023-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)

8. Competitive Landscape

  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Alpha Tau Medical Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fusion Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Telix Pharmaceuticals Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orano Group (Orano Med)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NOVARTIS AG (Endocyte Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Actinium Pharmaceutical Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us